107 related articles for article (PubMed ID: 30317268)
1. Evaluation of correlation between expression of P53 and Malondialdehyde levels in prostate cancer patients.
Arif M; Rashid A; Majeed A; Qaiser F; Razak S
J Pak Med Assoc; 2018 Sep; 68(9):1373-1377. PubMed ID: 30317268
[TBL] [Abstract][Full Text] [Related]
2. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
3. [Expressions of apoptosis-associated proteins in prostate carcinoma and their clinicopathological significance].
Zhang X; Li F; Jiang Y
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Jun; 31(2):193-6. PubMed ID: 12515134
[TBL] [Abstract][Full Text] [Related]
4. Association of Pb, Cd, and Se concentrations and oxidative damage-related markers in different grades of prostate carcinoma.
Guzel S; Kiziler L; Aydemir B; Alici B; Ataus S; Aksu A; Durak H
Biol Trace Elem Res; 2012 Jan; 145(1):23-32. PubMed ID: 21809052
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
6. [Cancer of the prostate: evaluation of the expression of the mutated protein of the 53 tumor suppressor gene].
Rivera P; Ibacache G; García M; Roa I; Orio M
Actas Urol Esp; 1997 Oct; 21(9):822-6. PubMed ID: 9471864
[TBL] [Abstract][Full Text] [Related]
7. THE RELATIONSHIP BETWEEN SERUM LEVEL OF MALONDIALDEHYDE AND PROGRESSION OF COLORECTAL CANCER.
Rašić I; Rašić A; Akšamija G; Radović S
Acta Clin Croat; 2018 Sep; 57(3):411-416. PubMed ID: 31168172
[TBL] [Abstract][Full Text] [Related]
8. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
9. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma.
Meyer-Siegler KL; Bellino MA; Tannenbaum M
Cancer; 2002 Mar; 94(5):1449-56. PubMed ID: 11920501
[TBL] [Abstract][Full Text] [Related]
10. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
11. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.
Kelavkar UP; Cohen C; Kamitani H; Eling TE; Badr KF
Carcinogenesis; 2000 Oct; 21(10):1777-87. PubMed ID: 11023533
[TBL] [Abstract][Full Text] [Related]
12. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
14. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I
Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the value of p53 protein expression in the extra-capsular extension of prostate cancer.
Saidi S; Georgiev V; Stavridis S; Penev M; Stankov O; Dohcev S; Banev S; Danilovski D; Ivanovski O; Popov Z
Prilozi; 2011; 32(2):213-20. PubMed ID: 22286625
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
18. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
20. Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features.
Machtens S; Serth J; Bokemeyer C; Bathke W; Minssen A; Kollmannsberger C; Hartmann J; Knüchel R; Kondo M; Jonas U; Kuczyk M
Int J Cancer; 2001 Sep; 95(5):337-42. PubMed ID: 11494236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
